


What is Claimed:

- 5 1. A crystalline hydrochloride salt or a crystalline maleate salt of a compound of formula:



- (i) the crystalline hydrochloride salt is characterized by an X-ray powder diffraction (XRPD) pattern comprising a characteristic peak at about $11^\circ 2\theta$; or
- 10 (ii) the crystalline maleate salt is characterized by an X-ray powder diffraction (XRPD) pattern comprising a characteristic peak at about $22.5^\circ 2\theta$.
2. A pharmaceutical composition comprising the crystalline hydrochloride salt or crystalline maleate salt of claim 1, and a pharmaceutically acceptable carrier and/or excipient.
3. Use of the crystalline hydrochloride salt or crystalline maleate salt of claim 1, in the
- 15 manufacture of a medicament, for treating a disease mediated by aberrant activity of FGFR in a subject in need thereof, wherein the disease is selected from the group consisting of breast cancer, multiple myeloma, bladder cancer, non-muscle invasive bladder cancer, endometrial cancer, gastric cancer, cervical cancer, rhabdomyosarcoma, lung cancer, squamous non-small cell lung cancer, urothelial cancer, renal cell carcinoma, ovarian cancer, esophageal cancer,
- 20 melanoma, colon cancer, liver cancer, hepatocellular carcinoma, head and neck squamous cell carcinoma, cholangiocarcinoma, glioma, 8,11 myeloproliferative syndrome, myeloproliferative disorders involving FGFR translocations/fusions, alveolar rhabdomyosarcoma, malignant rhabdoid tumors, glioblastoma, muscle invasive bladder, renal cancer, and prostate cancers.